secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001493152-26-008435
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics
--------------------------------------------------------------------------------

- Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).
- Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.
- CL-273 targets $16.2 billion lung cancer market; addresses resistance to existing EGFR TKIs.
- Binding term sheet signed March 2, 2026; closing subject to shareholder and NYSE American approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/0001493152-26-008435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer